Skip to main content
International Journal of Chronic Obstructive Pulmonary Disease logoLink to International Journal of Chronic Obstructive Pulmonary Disease
. 2019 Jan 18;14:241. doi: 10.2147/COPD.S194429

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum]

PMCID: PMC6343748  PMID: 30718948

Casas A, Montes de Oca M, Menezes AMB, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556.

Page 1552, Disclosure, the text “AM has been paid for her work as a statistician for the LASSYC study. LR is an employee of AstraZeneca. The other authors report no conflicts of interest in this work” should read “AMM has been paid by AstraZeneca and GlaxoSmithKline for her work as a statistician for the LASSYC and PLATINIO studies, respectively. LR is an employee of AstraZeneca. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.


Articles from International Journal of Chronic Obstructive Pulmonary Disease are provided here courtesy of Dove Press

RESOURCES